1. Home
  2. DGICA vs ARVN Comparison

DGICA vs ARVN Comparison

Compare DGICA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DGICA

Donegal Group Inc.

HOLD

Current Price

$18.90

Market Cap

714.2M

Sector

Finance

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.26

Market Cap

600.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGICA
ARVN
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
714.2M
600.2M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
DGICA
ARVN
Price
$18.90
$7.26
Analyst Decision
Buy
Buy
Analyst Count
2
16
Target Price
★ $21.00
$13.93
AVG Volume (30 Days)
93.5K
★ 646.8K
Earning Date
10-29-2026
11-04-2026
Dividend Yield
★ 4.01%
N/A
EPS Growth
N/A
★ 58.84
EPS
N/A
★ 1.70
Revenue
★ $978,014,322.00
$262,600,000.00
Revenue This Year
N/A
$12.76
Revenue Next Year
N/A
N/A
P/E Ratio
$7.82
★ $4.54
Revenue Growth
N/A
★ N/A
52 Week Low
$16.11
$6.74
52 Week High
$21.06
$14.22

Technical Indicators

Market Signals
Indicator
DGICA
ARVN
Relative Strength Index (RSI) 56.29 43.63
Support Level $18.02 $6.74
Resistance Level $19.54 $7.74
Average True Range (ATR) 0.43 0.36
MACD 0.11 0.08
Stochastic Oscillator 75.43 51.43

Price Performance

Historical Comparison
DGICA
ARVN

About DGICA Donegal Group Inc.

Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: